Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”
Edwin Choy,
Karla Ballman,
James Chen,
Mark A. Dickson,
Rashmi Chugh,
Suzanne George,
Scott Okuno,
Raphael Pollock,
Rajiv M. Patel,
Antje Hoering,
Shreyaskumar Patel
Affiliations
Edwin Choy
Massachusetts General Hospital, Division of Hematology Oncology, 55 Fruit Street, Boston, MA 02114, USA
Karla Ballman
Weill Cornell Medicine Healthcare Policy and Research, 402 East 67th Street, LA-225, New York, NY 10065, USA
James Chen
The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 250 Lincoln Tower, Columbus, OH 43210, USA
Mark A. Dickson
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E. 66th Street, New York, NY 10065, USA
Rashmi Chugh
University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Rm C-407 MIB/SPC 5843, Ann Arbor, MI 48109, USA
Suzanne George
Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, 450 Brookline Ave, D-1212, Brookline, MA 02215, USA
Scott Okuno
Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
Raphael Pollock
Ohio State University Wexner Medical Center, 410 West 10th Avenue, N924 Doan Hall, Columbus, OH 43206, USA
Rajiv M. Patel
Michigan Medicine, Department of Pathology, 1301 Catherine Street, SPC 5602, 3261G Medical Science I, Ann Arbor, MI 48109-5602, USA
Antje Hoering
Cancer Research and Biostatistics, 1730 Minor Ave, Suite 1900, Seattle, WA 98101, USA
Shreyaskumar Patel
MD Anderson Cancer Center, Sarcoma Medical Oncology, 1400 Holcombe Blvd, Unit 450, Houston, TX 77030, USA
